alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
Clinical trial NCT03692429 · RECRUITING
Trial details
- NCT number
- NCT03692429
- Sponsor
- Celyad Oncology SA
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-28
- Primary completion
- 2021-11-28
- Enrollment
- 49
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.